|
Imboden, M; Murphy, K R; Rakhmilevich, A L et al. (2001) The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res 61:1500-7
|
|
Sondel, P M; Hank, J A (2001) Antibody-directed, effector cell-mediated tumor destruction. Hematol Oncol Clin North Am 15:703-21
|
|
Turner, J G; Rakhmilevich, A L; Burdelya, L et al. (2001) Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J Immunol 166:89-94
|
|
Gan, J; Kendra, K; Ricci, M et al. (1999) Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins. Clin Diagn Lab Immunol 6:236-42
|
|
Sondel, P M (1999) Post-transplant immunotherapy designed to prevent cancer recurrence. Pediatr Transplant 3 Suppl 1:96-101
|
|
Kendra, K; Gan, J; Ricci, M et al. (1999) Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice. Cancer Immunol Immunother 48:219-29
|
|
Nicolet, C M; Surfus, J M; Hank, J A et al. (1998) Transcription factor activation in lymphokine activated killer cells and lymphocytes from patients receiving IL-2 immunotherapy. Cancer Immunol Immunother 46:327-37
|
|
Nicolet, C M; Siegel, D H; Surfus, J E et al. (1997) TAG-72-reactive antibody CC49 recognizes molecules expressed by hematopoietic cell lines. Tumour Biol 18:356-66
|
